IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.365
AS - Asia 3.686
EU - Europa 3.549
SA - Sud America 511
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 11
Totale 41.186
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.163
SG - Singapore 1.696
CN - Cina 867
DE - Germania 850
RU - Federazione Russa 466
IT - Italia 464
BR - Brasile 430
UA - Ucraina 430
HK - Hong Kong 388
IE - Irlanda 338
VN - Vietnam 302
GB - Regno Unito 269
FR - Francia 240
FI - Finlandia 155
CA - Canada 154
KR - Corea 119
SE - Svezia 104
JP - Giappone 82
PL - Polonia 64
IN - India 43
MX - Messico 38
AR - Argentina 32
AT - Austria 30
NL - Olanda 30
BD - Bangladesh 27
BE - Belgio 27
ID - Indonesia 21
ZA - Sudafrica 21
IQ - Iraq 20
ES - Italia 19
CZ - Repubblica Ceca 15
TR - Turchia 15
EC - Ecuador 14
UZ - Uzbekistan 14
PH - Filippine 13
CH - Svizzera 11
AU - Australia 10
EU - Europa 10
TH - Thailandia 10
IL - Israele 9
RO - Romania 9
PK - Pakistan 8
SA - Arabia Saudita 8
CL - Cile 7
CO - Colombia 7
VE - Venezuela 7
EG - Egitto 5
KE - Kenya 5
MA - Marocco 5
TN - Tunisia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
JM - Giamaica 4
KG - Kirghizistan 4
NO - Norvegia 4
PE - Perù 4
PY - Paraguay 4
TW - Taiwan 4
BG - Bulgaria 3
DZ - Algeria 3
GE - Georgia 3
HR - Croazia 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LT - Lituania 3
AM - Armenia 2
BB - Barbados 2
BW - Botswana 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MK - Macedonia 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
SN - Senegal 2
TG - Togo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
EE - Estonia 1
GT - Guatemala 1
KH - Cambogia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
VI - Stati Uniti Isole Vergini 1
Totale 41.185
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.716
Houston 7.678
Singapore 880
Ann Arbor 810
Fairfield 770
Ashburn 585
Chandler 585
San Jose 406
Jacksonville 390
Hong Kong 385
Beijing 359
Seattle 341
Dublin 324
New York 319
Cambridge 279
Medford 237
Dearborn 198
Munich 172
Rome 158
Santa Clara 138
Lawrence 114
Mcallen 111
Montréal 110
Los Angeles 107
Ho Chi Minh City 98
The Dalles 95
Moscow 80
Lauterbourg 77
Buffalo 75
Zhengzhou 73
Tokyo 69
Mülheim 68
Hanoi 66
Council Bluffs 63
Helsinki 60
Dallas 53
Menlo Park 52
Milan 49
São Paulo 46
San Diego 42
Kraków 40
Shanghai 36
Hefei 34
Guangzhou 29
London 27
Nuremberg 27
Orem 27
Chicago 25
Brooklyn 23
University Park 23
Atlanta 22
Norwalk 21
Brussels 20
Mountain View 20
Saint Petersburg 20
Frankfurt am Main 19
Nanjing 19
North Bergen 18
Redondo Beach 18
Phoenix 17
Warsaw 17
Redwood City 16
Stockholm 16
Toronto 16
Da Nang 15
Montreal 15
Creede 14
Palo Alto 14
Seoul 14
Falls Church 13
Kunming 13
Rio de Janeiro 13
Center 12
Haiphong 12
Jakarta 12
Johannesburg 12
San Francisco 12
Amsterdam 11
Belo Horizonte 11
Boardman 11
Brno 11
Engelhard 11
Nürnberg 11
Verona 10
Bologna 9
Boston 9
Columbus 9
Curitiba 9
Denver 9
Dhaka 9
Vienna 9
Wuhan 9
Baghdad 8
Biên Hòa 8
Brasília 8
Chennai 8
Hangzhou 8
Naples 8
Tashkent 8
Totale 35.429
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 877
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 574
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 514
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 512
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 489
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 487
Treatment of multiple myeloma: A randomized study of three different regimens 477
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 476
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 471
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 470
Non-Hodgkin lymphomas of the central nervous system 465
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 462
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 458
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 455
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 455
Comprehensive analysis of PTEN status in Sezary syndrome 455
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 454
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 452
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 445
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 445
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 442
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 442
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 439
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 438
FISH analysis for CML monitoring? 437
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 436
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 436
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 434
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 433
Peripheral polyneuropathy during treatment with alpha-2 interferon 431
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 428
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 427
Multiple skin tumors in long-term treatment with hydroxyurea 424
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 423
Biological and clinical advances in multiple myeloma: A review 419
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 415
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 414
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 413
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 412
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 412
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 408
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 408
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 408
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 407
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 404
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 403
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 403
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 402
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 402
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 402
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 401
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 400
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 400
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 400
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 399
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 399
Psoriasiform sarcoidosis: an unusual variety 399
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 394
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 393
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 391
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 390
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 388
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 387
Chemotherapy in cutaneous T-cell lymphoma 383
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 383
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 383
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 382
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 381
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 380
Monitoring treatment and survbival in Cronic Myeloid Leukemia 380
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 380
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 378
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 376
Surgical management of rhinosinusitis in onco-hematological patients 372
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 369
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 367
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 367
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 359
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 358
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 358
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 357
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 344
[Current aspects of treatment of multiple myeloma] 341
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 339
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 337
Granulomatous mycosis fungoides responsive to gemcitabine 333
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 327
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 278
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 230
Recurrent Sweet's syndrome in a patient with multiple myeloma 229
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 206
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 198
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 197
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 195
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 192
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 188
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance 186
Preliminary results of a counselling programme for fertility preservation in female cancer patients: the experience of the GEMME DORMIENTI network 179
Nephelometric assay of urine free light chains: An alternative and early clinical test for Bence-Jones protein quantification 178
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 176
Totale 39.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.187
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021339 0 0 0 0 0 0 0 0 0 0 284 55
2021/20221.054 43 107 20 76 30 99 44 42 76 87 55 375
2022/20231.581 167 150 77 160 131 349 180 79 137 10 112 29
2023/2024737 51 20 61 20 38 298 30 31 18 13 25 132
2024/20252.633 92 559 302 143 43 139 210 135 201 238 295 276
2025/20263.884 313 222 516 346 404 200 502 475 441 418 47 0
Totale 41.496